Mankind Pharma's shares surged more than 8% on October 27, 2026, after the company reported strong earnings for the second quarter. The pharmaceutical firm beat market expectations with healthy revenue gains and improved profit margins, signaling further growth potential ahead.
- Mankind Pharma's shares increased 8.13% to an intraday high of ₹2,500.
- Q2 revenue rose 17.3% year-on-year to ₹4,338 crore.
- Net profit grew 39% year-on-year to ₹711 crore.
- EBITDA margins expanded by 210 basis points to 27.1%.
- Both domestic and international business segments showed strong growth.
What drove Mankind Pharma's strong Q2 earnings?
The company’s revenue from core operations increased by 17.3% compared to the same quarter last year, reaching ₹4,338 crore. This growth was supported by strong performance in both domestic and international markets. Domestic revenues grew 15.9%, while international revenues surged 33%, driven by Mankind and BSV International.
Net profit for the quarter rose 39% year-on-year to ₹711 crore, surpassing market estimates. Operating profit also improved significantly by 27.2% to ₹1,175 crore. The company’s operating margins expanded to 30%, up from 27% in the previous year.
How did profit margins improve?
Mankind Pharma’s EBITDA margins increased by 210 basis points to 27.1% in Q2 FY27, compared to 25% in the same quarter last year. This improvement was due to better gross margins, operating leverage, and lower research and development expenses. The company also benefited from higher other income and a slightly lower effective tax rate, which contributed to the net profit beat.
What are analysts saying about future growth?
Analysts from JPMorgan raised their EBITDA estimates by 3% to 4%, citing better visibility in India’s prescription drugs market and export growth. However, they maintained a neutral rating, waiting for more consistent performance in India and clearer consumer trends.
Macquarie analysts noted that the EBITDA beat was driven by revenue growth, improved margins, and cost control. Bernstein analysts pointed out that seasonal demand and an easier base helped growth but cautioned against extrapolating headline growth too far.
Jefferies experts highlighted that muted consumer healthcare growth was a concern, but overall, the company’s strong domestic and export performance was promising.
What challenges and opportunities lie ahead?
The company’s domestic business showed strong volume growth, but the sustainability of this outperformance remains to be seen. The over-the-counter drugs segment remained weak in Q2, which could affect future earnings.
On the positive side, Mankind Pharma launched one new product during the quarter, bringing its total products launched in the United States to 50. This expansion in the US market offers growth opportunities alongside the strong performance in India and exports.
Frequently Asked Questions
Q: How much did Mankind Pharma's shares rise after Q2 earnings?
A: The shares rose 8.13% to an intraday high of ₹2,500 on October 27, 2026.
Q: What was the net profit growth in Q2 FY27?
A: Net profit increased by 39% year-on-year to ₹711 crore.
Q: Which markets contributed to the revenue growth?
A: Both domestic and international markets contributed, with domestic revenue up 15.9% and international revenue up 33%.
Q: What are analysts' views on future growth?
A: Analysts are optimistic about EBITDA growth due to better visibility in India’s prescription drugs market and exports but remain cautious about consumer healthcare trends.
